Harry Nguyen: Most of IR literature in this space was retrospective until DOSIPHERE and the incorporation of personalized dosimetry
Harry Nguyen, Assistant Professor at UCI Health Physicians, recently shared a post by Krishan Jethwa, Radiation Oncologist at Mayo Clinic, on X, adding:
“Most of IR literature in this space was retrospective until DOSIPHERE and the incorporation of personalized dosimetry. Hard to compare across eras. Like now, standard SBRT uses IMRT.
I think the only HCC trial I lean on in radiation is RTOG1112 but that’s just my ignorance. If institutions don’t give radiation oncology a shot and every tumor is put into an IRAD trial or transplant you’re never going to get any data, positive or negative and you’ll always need ‘further studies’.
We need more radiation data that isn’t just limited (in my experience) to mostly extrahepatic Mets, palliative, and salvage therapy.”
Quoting Krishan Jethwa’s post:
“But within Legacy, 62% were < 3 cm and 93% were </= 5 cm.
These are quotes from BCLC. Within the same paragraph, suggestion of the limitations of data for SBRT (further prospective study needed) and then quoting a retrospective study supporting y90.”
Sources: Harry Nguyen/X and Krishan Jethwa/X
-
ESMO 2024 Congress
September 13-17, 2024
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023